Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-04-04
2006-04-04
Coleman, Brenda (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S557000
Reexamination Certificate
active
07022698
ABSTRACT:
Pharmaceutical compositions containing Form III, Form IV, Form V olanzapine and/or pharmaceutically acceptable salts thereof. The pharmaceutical compositions are useful for the treatment of psychotic conditions, mild anxiety and gastrointestinal conditions. In particular, the compositions are useful for treating schizophrenia and related disorders, acute mania, Bipolar I Disorder, psychotic mood disorder and psychosis in patients with Alzheimer's disease.
REFERENCES:
patent: 4115568 (1978-09-01), Chakrabarti et al.
patent: 4115574 (1978-09-01), Chakrabarti et al.
patent: 5229382 (1993-07-01), Chakrabarti et al.
patent: 5457101 (1995-10-01), Greenwood et al.
patent: 5605897 (1997-02-01), Beasley, Jr. et al.
patent: 5627178 (1997-05-01), Chakrabarti et al.
patent: 5631250 (1997-05-01), Bunnell et al.
patent: 5637584 (1997-06-01), Larsen
patent: 5696115 (1997-12-01), Rasmussen
patent: 5703232 (1997-12-01), Bunnell et al.
patent: 5736541 (1998-04-01), Bunnell et al.
patent: 5817655 (1998-10-01), Chakrabarti et al.
patent: 5817656 (1998-10-01), Beasley, Jr. et al.
patent: 5817657 (1998-10-01), Beasley, Jr. et al.
patent: 5919485 (1999-07-01), Cochran et al.
patent: 6251895 (2001-06-01), Larsen et al.
patent: 0733635 (1996-09-01), None
patent: 0831097 (1998-03-01), None
patent: WO 0018408 (2000-04-01), None
Houben-Weyl, “Methoden der organischen Chemie, Band I/1, Allgemeine Laboratoriumsprazis I” 1958, Georg Thieme Verlag, Stuttgart XP002163768, pp. 381-382.
R. Narendran et al. “Olanzapine Therapy in Treatment-Resistant Psychotic Mood Disorders: A Long-Term Follow-Up Study”,J Clin Psychiatry.62:7, Jul. 2001, pp. 509-516.
J. Kando et al. “Olanzapine: A new Antipsychotic Agent with Efficacy in the Management of Schizophrenia”,The Annals of Pharmacotherapy.Nov., 1997, vol. 31, pp. 1325-1334.
P. Tran et al. “Double-Blind Comparison of Olanzapine Versus Risperidone in the Treatment of Schizophrenia and Other Psychotic Disorders”,Journal of Clinical Psychopharmacology.vol. 17, No. 5, pp. 407-418, 1997.
F. Bymaster et al. “In Vitro and In Vivo Biochemistry of Olanzapine: A Novel, Atypical Antipsychotic Drug”,J Clin Psychiatry.1997; 58 (suppl 10), pp. 28-36.
C. Beasley et al. “Efficacy of Olanzapine: An Overview of Pivotal Clinical Trials”,J Clin Psychiatry.1997; 58 (suppl 10), pp. 7-12.
W. Glazer. “Olanzapine and the New Generation of Antipsychotic Agents: Patterns of Use”,J Clin Psychiatry.1997; 58 (suppl 10), pp. 18-21.
The Medical Letter, “On Drugs and Therapeutics”. Jan. 17, 1997, vol. 38 (Issue 992), pp. 5-6.
C. Nemeroff. “Dosing the Antipsychotic Medication Olanzapine”,J Clin Psychiatry.1997; 58 (suppl 10), pp. 45-49.
C. Guille et al. “A Naturalistic Comparison of Clozapine, Risperidone, and Olanzapine in the Treatment of Bipolar Disorder”,J Clin Psychiatry.61:9, Sep. 2000, pp. 638-642.
W. Clark et al. “The Effects of Olanzapine in Reducing the Emergence of Psychosis Among Nursing Home Patients with Alzheimer's Disease”,J Clin Psychiatry.62:1, Jan. 2001, pp. 34-39.
K. Littrell et al. “Switching Clozapine Responders to Olanzapine”,J Clin Psychiatry.61:12, Dec. 2000, pp. 912-915.
J. Gomez et al. “Superior Efficacy of Olanzapine Over Haloperidol: Analysis of Patients with Schizophrenia From a Multicenter international Trial”,J Clin Psychiatry.2001:62, (suppl 2), pp. 6-10.
M. Tohen et al. “Olanzapine Versus Placebo in the Treatment of Acute Mania”,Am J Psychiatry.156:5, May 1999, pp. 702-709.
Drugs of the Future,Olanzapine,1994, vol. 19(2), pp. 114-117.
Chakrabarti et al.,4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as Potential Neuroleptics,J. Med. Chem, 1980, vol. 23, pp. 878-884.
Chakrabarti, et al.,10-Piperazinyl-4H-thieno[3,2-b][1-5]- and -[3,4-b][1,5]benzodiazepines as Potential Neuroleptics,J. Med. Chem. 1980, vol. 23, 884-889.
Chakrabarti, et al.,Effects of Conformationally Restricted 4-Piperazinyl-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems,J. Med. Chem., 1982, vol. 25, pp. 1133-1140.
Schmitt et al., Targeting Nicotinic Acetylcholine Receptors: Advances in Molecular Design and Therapies, Annual Reports in Medicinal Chemistry, vol. 35, pp. 41-51, 2000.
Hamied Yusuf K.
Kankan Rajendra N.
Rao Dharmaraj R.
Coleman Brenda
Haddaway Keith G.
Petruzzelli Julie
U & I Pharmaceuticals Ltd.
Venable LLP
LandOfFree
Pharmaceutical compositions containing new polymorphic forms... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions containing new polymorphic forms..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions containing new polymorphic forms... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3558833